Passage Bio

PASGPhase 2

Passage Bio is dedicated to fulfilling the promise of genetic medicine by developing transformative therapies for people with devastating CNS diseases. The company leverages its expertise in AAV vector engineering and delivery to target monogenic neurodegenerative disorders with high unmet need. With two lead programs in Phase 1/2 clinical trials and a strategic collaboration with the University of Pennsylvania's Gene Therapy Program, Passage Bio is positioned at the forefront of CNS gene therapy. Their mission centers on turning disbelief into belief and transforming the lives of patients and their families.

Market Cap

$23.8M

Employees

50-100

Focus

RNA & Gene Therapy

AI Company Overview

Technology Platform

AAV-based gene therapy platform focused on engineered capsids and optimized delivery techniques, particularly intracisternal magna injection, for targeting monogenic central nervous system disorders.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
PBFT02	Frontotemporal Dementia	Phase 1/2

Opportunities

Significant opportunity in ultra-orphan and monogenic CNS diseases with no approved disease-modifying therapies.

Successful gene therapies can command premium pricing.

The platform's potential can be expanded to other CNS targets beyond the current lead indications.

Risk Factors

High clinical trial failure risk, complex AAV manufacturing and scalability challenges, regulatory hurdles for novel gene therapies, finite cash runway requiring future dilutive financing, and intense competition in the neurology space.

Competitive Landscape

Faces competition from other gene therapy developers (e.g., Neurocrine, Sio) and different therapeutic modalities (ASOs, small molecules) in FTD. In GM1, it is among a small group of gene therapy developers. Differentiation relies on AAVhu68 capsid, ICM delivery for broad distribution, and the Penn GTP collaboration.